智通财经APP获悉，百心安-B(02185)现涨超4%，截至发稿，涨4.13%，报6.56港元，成交额118.24万港元。
消息面上，百心安此前公告，附属公司上海安通医疗科技有限公司研发的Iberis 多极肾动脉射频消融导管系统已在新西兰完成注册。Iberis RDN系统是全球唯一获准使用经桡动脉方法和经股动脉入路方法的肾神经阻断产品。
华福证券此前发布研报称，百心安 Iberis RDN 系统是全球唯一获批上市能兼具经桡动脉（TRA）和经股动脉双入路 RDN，先发优势显著，国内已与远大健康、海外多国家地区联合蓝帆柏盛达成重磅战略合作；德国、法国已将 Iberis RDN 纳入医保，当前正为百心安商业化加速起点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.